{"id":"W4306247391","doi":"10.1016/s2213-2600(22)00309-5","title":"Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial","year":2022,"lang":"en","type":"article","venue":"The Lancet Respiratory Medicine","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":120,"is_retracted":false,"has_abstract":false,"ca_institutions":"Regional Municipality of Durham; Lakeridge Health","funders":"Chugai Pharmaceutical; Genentech; Ipsen; Jazz Pharmaceuticals; Daiichi Sankyo Europe; Sanofi; GlaxoSmithKline; Servier; Amgen; Pfizer; PharmaMar; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Clinical endpoint; Chemotherapy; Population; Febrile neutropenia; Oncology; Doxorubicin; Topotecan; Vincristine; Anthracycline; Clinical trial; Surgery; Cyclophosphamide; Cancer; Neutropenia; Breast cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001692139,0.001865508,0.003715174,0.000460551,0.0004294563,0.001259618,0.001171871,0.002196795,0.007348928],"category_scores_gemma":[0.001695208,0.0007219941,0.002273451,0.0005047231,0.001491325,0.001305792,0.0005399217,0.004155117,0.001310575],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001164005,"about_ca_system_score_gemma":0.001175463,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001852477,"about_ca_topic_score_gemma":0.004279659,"domain_scores_codex":[0.9993117,0.0003851769,0.00002808555,0.0001264475,0.00003721274,0.0001114353],"domain_scores_gemma":[0.9988952,0.0003728871,0.0002104778,0.00007404618,0.00004528943,0.0004020498],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9852213,0.003454834,0.0003553096,0.0003283153,0.0005464078,0.00001876712,0.0000395639,0.0002594215,0.0009809454,0.00006839113,0.0004797012,0.00824704],"study_design_scores_gemma":[0.9510576,0.04713849,0.0008201525,0.00001938652,0.0002496855,0.00001535989,0.00002072902,0.0002360042,0.0001051386,0.00007096897,0.0002556831,0.00001090858],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9892266,0.0049724,0.0003644629,0.0009487774,0.0006780668,0.001329504,0.0008024774,0.0001097713,0.001567904],"genre_scores_gemma":[0.9886048,0.002597718,0.001084992,0.001070503,0.0004840833,0.001775648,0.001064765,0.00002516554,0.003292442],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007348928,"threshold_uncertainty_score":0.02458459,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0657955502563836,"score_gpt":0.3892918764154446,"score_spread":0.323496326159061,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}